Evidence map›Paper›PMID 38240863›Full record

ArticleCancer immunology, immunotherapy : CII2024

Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.

Thomas Eichholz, Florian Heubach, Anne-Marie Arendt, Christian Seitz, Ines B Brecht, Martin Ebinger, Tim Flaadt, Daniela Süsskind, Lisa Richter, Isabel Hülsenbeck and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Retinoblastoma and Its Tumor Microenvironment.Current oncology (Toronto, Ont.) · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Update on Retinoblastoma Therapies.Medicina (Kaunas, Lithuania) · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Thomas EichholzUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany. Thomas.eichholz@med.uni-tuebingen.de.
Florian HeubachUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
Anne-Marie ArendtUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
Christian SeitzUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
Ines B BrechtUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
Martin EbingerUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
Tim FlaadtUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
Daniela SüsskindDepartment of Ophthalmology, Eberhard Karls University, Tuebingen, Germany.
Lisa RichterDepartment of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Isabel HülsenbeckDepartment of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Leonie ZerweckDepartment of Radiology, Diagnostic and Interventional Neuroradiology, Eberhard Karls University, Tuebingen, Germany.
Sophia GörickeDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Frank PaulsenDepartment of Radiation Oncology, Eberhard Karls University, Tuebingen, Germany.
Frank DombrowskiInstitute of Pathology, University Medicine of Greifswald, Greifswald, Germany.
Christian FlothoDivision of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Stefan SchönbergerDepartment of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Petra KettelerDepartment of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Johannes SchulteUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
Peter LangUniversity Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
University Children's Hospital Tübingen · DEUniversity of Duisburg-Essen · DEUniversity of Tübingen · DEUniversitätsmedizin Greifswald · DEUniversity Medical Center Freiburg · DE

Funding

excellence cluster iFIT (EXC 2180) [Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Länder] WXC 2180 - 390900677
6 · The paper itself

Abstract

backgroundGD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors.

methodsThe German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclonal antibody (mAb) dinutuximab beta (Db) in order to evaluate toxicity, response and outcome in these patients. Additionally, we evaluated anti-GD2 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in retinoblastoma cell lines in vitro. Furthermore, in vitro cytotoxicity assays directed against B7-H3 (CD276), a new identified potential target in RB, were performed.

resultsWe identified four patients with relapsed stage IV retinoblastoma, who were treated with Db following autologous stem cell transplantation (ASCT). Two out of two evaluable patients with detectable tumors responded to immunotherapy. One of these and another patient who received immunotherapy without residual disease relapsed 10 and 12 months after start of Db. The other patients remained in remission until last follow-up 26 and 45 months, respectively. In vitro, significant lysis of RB cell lines by ADCC and CDC with samples from patients and healthy donors and anti-GD2 and anti-CD276-mAbs were demonstrated.

conclusionAnti-GD2-directed immunotherapy represents an additional therapeutic option in high-risk metastasized RB. Moreover, CD276 is another target of interest.

Indexed as

Hematopoietic Stem Cell TransplantationRetinal NeoplasmsRetinoblastomaB7 AntigensGangliosidesHumansImmunotherapyNeoplasm Recurrence, LocalTransplantation, AutologousB7 AntigensCD276 protein, humanGangliosidesB7-H3CD276Dinutuximab betaGD2RetinoblastomaTargeted therapy

Identifiers

PMID38240863
PMCPMC10798927
OpenAlexW4391036266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.